P-222 Analysis of tumour contours and radiotherapy planning of 'on-trial' patients undergoing chemoradiotherapy (CRT) in SCALOP trial: does pre-trial Radiotherapy Quality Assurance (RTQA) improve the quality of 'on-trial' radiotherapy?

Fokas, E., Spezi, E. ORCID: https://orcid.org/0000-0002-1452-8813, Patel, N., Hurt, C. ORCID: https://orcid.org/0000-0003-1206-8355, Nixon, L. ORCID: https://orcid.org/0000-0002-1270-6970, Chu, K., Joseph, G., Staffurth, J. ORCID: https://orcid.org/0000-0002-7834-3172, Abrams, R. and Mukherjee, S. 2016. P-222 Analysis of tumour contours and radiotherapy planning of 'on-trial' patients undergoing chemoradiotherapy (CRT) in SCALOP trial: does pre-trial Radiotherapy Quality Assurance (RTQA) improve the quality of 'on-trial' radiotherapy? Annals of Oncology 27 (sup. 2) , ii64.3-ii65. 10.1093/annonc/mdw199.214

Preview

PDF - Accepted Post-Print Version Download (55kB) | Preview

Abstract

The SCALOP trial tested the safety and efficacy of gemcitabine (Gem) versus capecitabine (Cap) based CRT following induction chemotherapy and showed that GemRT was associated with greater toxicity and worse survival1. The evaluation of investigator-delineated volumes and plan assessment from the pre-trial RTQA program using a single benchmark case showed considerable variation in gross tumour volume (GTV) outlining but no major deviations in other aspects of RT planning.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Engineering Medicine
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) T Technology > TS Manufactures
Publisher:	Oxford University Press (OUP)
ISSN:	0923-7534
Date of First Compliant Deposit:	4 July 2016
Date of Acceptance:	15 April 2016
Last Modified:	23 Nov 2024 18:15
URI:	https://orca.cardiff.ac.uk/id/eprint/92274

Actions (repository staff only)

Edit Item